DRUG ファイナンス： Bright Minds Biosciences Inc AI分析

ホーム

株式

DRUG

財務状況

DRUG 財務

Bright Minds Biosciences Inc

$71.72

-1.71%

$-1.25

終値： Apr 01, 16:00:00 GMT-4

$71.72

アフターマーケット：Apr 01, 20:00:00 GMT-4

概要予測収入配当財務状況

収入

貸借対照表

現金の流れ

年次

四半期

DRUG 収入

金額は百万米ドル単位。会計年度は2月から1月まで。

Breakdown	TTM	09/30/2025	09/30/2024	09/30/2023	09/30/2022	09/30/2021
収入	0	0	0	0	0	0
収益成長率（YoY）	--	--	--	--	--	--
収益のコスト	--	--	--	--	--	--
売上総利益	--	--	--	--	--	--
販売、一般および管理	3	2	1	2	2	2
研究開発	15	11	1	4	12	6
運営費用	19	13	2	7	14	8
その他の非営業収入（費用）	--	--	--	--	--	--
税引前利益	-19	-12	-2	-7	-14	-8
所得税費	--	--	--	--	--	--
純利益	-19	-12	-2	-7	-14	-8
純利益成長率	1,800%	500%	-71%	-50%	75%	--
流通済み株式数（希薄化後）	7.76	6.87	4.31	3.71	2.47	1.79
株式変動（前年比）	26%	60%	16%	51%	38%	40%
EPS（希薄化）	-2.55	-1.77	-0.65	-1.98	-6.05	-4.81
EPS成長率	1,400%	174%	-67%	-67%	26%	1,185%
フリーキャッシュフロー	-13	-8	-1	-7	-13	-7
1株当たりフリーキャッシュフロー	--	--	--	--	--	--
粗利益	--	--	--	--	--	--
営業利益率	0%	0%	0%	0%	0%	0%
利益率	0%	0%	0%	0%	0%	0%
フリーキャッシュフロー利益率	0%	0%	0%	0%	0%	0%
EBITDA	-19	-13	-2	-7	-14	--
EBITDAマージン	0%	0%	0%	0%	0%	--
D&A による EBITDA	0	0	0	0	0	--
営業利益	-19	-13	-2	-7	-14	-8
営業利益率	0%	0%	0%	0%	0%	0%
実効税率	--	--	--	--	--	--

Follow-Up Questions

Bright Minds Biosciences Inc의 주요 재무제표는 무엇인가요?



최신 재무제표(Form-10K)에 따르면, Bright Minds Biosciences Inc의 총 자산은 $84이며, 순損失입니다.

DRUG의 주요 재무 비율은 무엇인가요?



Bright Minds Biosciences Inc의 유동비율은 42이고, 순이익률은 0, 주당 매출은 $0입니다.

Bright Minds Biosciences Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?



Bright Minds Biosciences Inc の最大収益セグメントは Machine Clothing で、最新の利益発表における収益は 749,907,000 です。地域別に見ると、United States が Bright Minds Biosciences Inc の主要市場であり、収益は 650,532,000 です。

Bright Minds Biosciences Inc은 수익성이 있나요?



いいえ, 최신 재무제표에 따르면 Bright Minds Biosciences Inc의 순損失은 $-12입니다.

Bright Minds Biosciences Inc에 부채가 있나요?



はい, Bright Minds Biosciences Inc의 부채는 2입니다.

Bright Minds Biosciences Inc의 발행 주식은 몇 주인가요?



Bright Minds Biosciences Inc의 총 발행 주식은 7.63주입니다.

主要データ

前終値

$72.97

始値

$74.68

当日レンジ

$69.24 - $75.99

52週レンジ

$23.17 - $123.75

取引高

192.6K

平均取引高

167.5K

配当利回り

1株当たり利益(TTM)

-2.02

時価総額

$702.1M

Bright Minds Biosciences Inc.とは何ですか？

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

特徴

リソース